Hopital D'Instruction Des Armees Percy
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The department is advancing research on blood‑borne malignancies, integrating novel immunotherapies and stem‑cell strategies to improve patient outcomes.
- Evaluation of novel immunotherapies for Acute Lymphoblastic Leukemia
- Combination approaches targeting Acute Myeloid Leukemia with FLT3 mutations
- Post‑transplant maintenance regimens in Multiple Myeloma
- MRD‑guided treatment adaptation for Acute Myeloid Leukemia
Hopital D'Instruction Des Armees Percy supports these studies within its dedicated hematology unit in Clamart, France.
Neoplasms
Oncology trials at the site focus on solid tumors, emphasizing targeted agents, immunotherapy combinations, and strategies to manage treatment‑related complications.
- Targeted immunotherapy for Non‑Small Cell Lung Cancer
- Bevacizumab‑based regimens for brain radionecrosis following metastasis treatment
- Chemotherapy plus checkpoint inhibitors in Advanced Lung Cancer
- Molecularly driven investigations in Glioblastoma
The research team collaborates with national cancer networks to bring innovative options to patients in the Paris region.
Bacterial Infections and Mycoses
Infectious disease studies aim to refine antifungal and antibacterial prophylaxis, particularly for immunocompromised and transplant populations.
- Azithromycin versus clarithromycin for Mycobacterium avium complex lung disease
- Six‑month itraconazole plus nebulised amphotericin regimen for Chronic Pulmonary Aspergillosis
- Oral vancomycin prophylaxis to prevent Clostridioides difficile infection in transplant patients
- Antifungal strategy assessment in immunocompromised hosts
These trials contribute to safer infection management for patients receiving hematopoietic stem cell transplantation at the hospital.
Immune System Diseases
Research on immune‑mediated conditions explores cytokine modulation, antibody therapies, and strategies to reduce treatment‑related inflammation.
- Tocilizumab discontinuation strategies in Giant Cell Arteritis
- Anti‑CD38 antibody use for post‑transplant immune reconstitution
- Immune‑modulating agents for Brain radionecrosis
- Novel approaches to autoimmune hematologic complications
The department leverages its expertise in immunology to test therapies that may reduce reliance on long‑term corticosteroids.
Cardiovascular Diseases and Thrombosis
Cardiovascular research addresses clotting disorders and bleeding risk, especially in the context of cancer treatment and transplantation.
- Full‑dose anticoagulation versus combined antiplatelet therapy in acute Venous Thromboembolism
- Prevention of Cancer‑Associated Thrombosis with monoclonal antibody REGN7508
- Circulatory physiology monitoring in transplant recipients
- Bleeding risk assessment for patients on anticoagulants and antiplatelet agents
Ongoing trials aim to optimize cardiovascular safety while maintaining effective oncologic care at Hopital D'Instruction Des Armees Percy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 68 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital D'Instruction Des Armees Percy
lock Showing 1 of 33 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial Comparing Azithromycin and Clarithromycin in Mycobacterium Avium Complex Pulmonary Disease Treatment | Centre Hospitalier Universitaire Amiens Picardie | Phase III | Recruiting | Feb 2018 | — |
IMP list
lock Showing 1 of 68 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azacitidine | 6 | Unknown | 2019-06-19 | 2025-03-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.